Prevention & lipidsTrial design
Rationale, design, and baseline characteristicss of the effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection: EPIC-HIV randomized clinical trial
- randomized, placebo-controlled, and double-blinded clinical trial
- 2:1 randomization
- rationale, design, and baseline characteristics report
Study context
- Population
- Adults at least 40 years old with treated and virally suppressed HIV and at least one cardiovascular risk factor (primary prevention) or a prior cardiovascular event (secondary prevention)participants randomized
- Participants
- One hundred eighteen adults
- Planned comparison
- alirocumab vs matching placebo
- Primary endpoint
- Change in arterial inflammation assessed using the target-to-background ratio of the most diseased arterial segment on positron emission tomography/computed tomography
- Follow-up
- Baseline to 1 year
No results yet. This paper sets out the design of a trial; its results are to come.
Baseline
Baseline characteristics
- Mean age
- 59.5 years
- Female
- 6%
Original publication
Rationale, design, and baseline characteristicss of the effect of PCSK9 inhibition on cardiovascular risk in treated HIV infection: EPIC-HIV randomized clinical trial. Am Heart J. Published 28 February 2026. doi:10.1016/j.ahj.2026.107400
Summarised from the published abstract; every number is checked against it